Emina Karahmet¹*, Besim Prnjavorac², Tamer Bego³, Neven Meseldžić³, Selma Imamović³, Esma Karahmet⁴, Farooq Sher⁵, Lana Lekić⁶ and Edin Begić⁷

¹Department of Biochemistry and Molecular Biology, University of Tuzla, Faculty of Pharmacy, Tuzla, Bosnia and Herzegovina
²Department of Pathophysiology, University of Sarajevo, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina
³Department of Biochemistry and Clinical Analysis, University of Sarajevo, Faculty of Pharmacy, Sarajevo, Bosnia and Herzegovina
⁴Department of Food and Nutrition Research, Juraj Strossmayer University of Osijek, Faculty of Food Technology, Croatia
⁵Department of Engineering, School of Science and Technology, Nottingham Trent University, Nottingham NG11 8NS, United Kingdom
⁶Department of Pharmacology and Clinical Pharmacy, University of Modern Sciences, Faculty of Pharmacy, Bosnia and Herzegovina
⁷Department of Pharmacology, Sarajevo School of Science and Technology, Sarajevo, Bosnia and Herzegovina

*Corresponding Author:Emina Karahmet, Department of Biochemistry and Molecular Biology, University of Tuzla, Faculty of Pharmacy, Tuzla, Bosnia and Herzegovina.

Received: June 22, 2021; Published: August 07, 2021

Abstract

The aim of this research study was to compare interleukin 1β (IL-1β) levels in participants with diabetes mellitus 2 (DM2) depending on the duration of disease and comorbidity.

Methods: A total number of 150 participants were observed by two different ways. In a first observation, all participants were grouped into four different groups (A, B, C, K), with criteria duration of DMT2: A- less than 10, B- 10-20, C- 20-30 years of DMT2 duration. Second observation was conducted with criteria accompanied comorbidities of DMT2, and all participants were grouped into 5 different groups (1: DMT2+ polyneuropathy (PNP) + hypertension, 2: DMT2 + PNP, 3: DMT2 + hypertension, 4: DM, 5: control). Each group included 30 participants, except group A in first observation that included 60 participants. Control group included 30 healthy participants. An enzyme-linked immunosorbent assay (ELISA) was performed to measure IL-1β levels in each group.

Results: In the first evaluation, IL-1β of the group C (98.43 pg/ml ± 5.72) was at a significantly lower level compared to group A 113.49 pg/mL ± 5.29 and B 114.53 pg/ml ± 5.69, and was not significantly different than control group K 98.88 pg/ml ± 14.42 (p = 0.002). IL-1β in group A was significantly different to group K, p = 0.0001, and group B was significantly different to group K, p = 0.003. IL-1β did not show a significant correlation with diabetic polyneuropathy.

In the second evaluation, IL-1β (pg/ml) was significantly different in groups (p < 0.001) with average ranges per groups: group 1: 93.84, group 2: 63.76, group 3: 86.69, group 4: 69.42 and group 5: 47.97. Groups 1 and 2 were significantly different (40.09 vs. 27.29, p = 0.007), groups 1 and 5 were significantly different (45.97 vs. 22.03, p < 0.001) and groups 3 and 5 show significant difference between each other (38.96 vs. 22.94, p < 0.001).

Conclusion: Hypertension has bigger impact to IL-1β ranges than diabetic neuropathy, but showed that hypertension and neuropathy are correlated and will probably be risk factors for the manifestation of another comorbidity in diabetic participants.

Keywords: Interleukins; Inflammation; Diabetes Mellitus; Hypertension; Diabetic Neuropathy

References

1. Marsha LT., et al. “Risk factors for macro and microvascular complications among older adults with diagnosed type 2 Diabetes: Findings from the Irish longitudinal study on ageing”. Journal of Diabetes Research (2016).
2. Papatheodorou K., et al. “Complications of Diabetes”. Journal of Diabetes Research (2016).
3. Russell WJ and Zilliox AL. “Diabetic Neuropathies”. Continuum (2014): 1226-1240.
4. Volmer-Thole M and Lobmann R. “Neuropathy and Diabetic Foot Syndrome”. International Journal of Molecular Sciences 17 (2016): 917.
5. Peiro C., et al. “IL-1β inhibition in cardiovascular compliactions associated to Diabetes Mellitus”. Frontiers in Pharmacology 8 (2017): 363.
6. Gomez D., et al. “Interleukin-1β promotes atheroprotective changes of advanced atherosclerotic lesions in mice”. Nature Medicine9 (2018): 1418-1429.
7. American Diabetes Association. “Diagnosis and Classification of Diabetes Mellitus”. Diabetes Care1 (2004): S5-S10.
8. Zhou H., et al. “Progress on diabetic cerebrovascular diseases”. Bosnian Journal of Basic Medical Sciences 4 (2014): 185-190.
9. Anquetil F., et al. “Alpha Cells, The Main Source of IL-1β in Human Pancreas”. Journal of Autoimmunity 81 (2017): 68-73.
10. Qi Tan., et al. “Potential roles of IL-1β subfamily members in glycolysis in disease”. Cytokine and Growth Factor Reviews 44 (2018): 18-27.
11. Butkowski E and Jelinek H. “Hyperglycaemia, oxidative stress and inflammatory markers”. Redox Report 22 (2017): 257-264.
12. Ismail CAN., et al. “Imbalanced oxidative stress and pro-inflammatory markers differentiate the development of diabetic neuropathy variants in streptozotocin- induced diabetic rats”. Journal of Diabetes and Metabolic Disorders 17 (2018): 129-136.
13. Liu Z., et al. “Circulating interleukin-1β promotes endoplasmic reticulum stress-induced myocytes apoptosis in diabetic cardiomyopathy via interleukin-1 receptor-associated kinase-2”. Cardiovascular Diabetology 14 (2015): 125.
14. Monnerat G., et al. “Macrophage- dependent IL-β production induces cardiac arrhythmias in diabetic mice”. Nature Communications 7 (2016): 13344.
15. Sager H., et al. “Interleukin-1β reduces leukocyte production after acute myocardial infarction”. Circulation20 (2015): 1880-1890.

Citation

Citation: Emina Karahmet., et al. “IL-1β in Correlation to the Common Diabetic Complications”.Acta Scientific Medical Sciences 5.9 (2021): 25-29.

Copyright

Copyright: © 2021 Emina Karahmet., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.